HINT3 and pulmonary arterial hypertension: Additionally, to demonstrate the therapeutic feasibility of targeting the USP11-HINT3 axis, studies are needed to investigate whether pharmacologic inhibition or genetic ablation of USP11 attenuates rodent models of PAH.